Compounds > latrunculol a
Page last updated: 2024-11-13

latrunculol a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

latrunculol A: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25150345
CHEMBL ID487774
CHEBI ID69127
MeSH IDM0554536

Synonyms (5)

Synonym
chebi:69127 ,
CHEMBL487774
latrunculol a
Q27137467
(4r)-4-[(1r,4z,8s,9s,10z,12s,15r,17r)-8,9,17-trihydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-17-yl]-1,3-thiazolidin-2-one

Research Excerpts

Overview

Latrunculol A is a recently discovered 6,7-dihydroxy analog of the potent actin inhibitor latrunculin A.

ExcerptReferenceRelevance
"Latrunculol A is a recently discovered 6,7-dihydroxy analog of the potent actin inhibitor latrunculin A. "( Development and validation of a rapid method for the detection of latrunculol A in plasma.
Amagata, T; Crews, P; Johnson, TA; Media, J; Shaw, J; Tenney, K; Valeriote, FA, 2010)		2.04

Bioavailability

ExcerptReferenceRelevance
" Currently, there are no reports regarding the bioavailability of latrunculol A in vivo."( Development and validation of a rapid method for the detection of latrunculol A in plasma.
Amagata, T; Crews, P; Johnson, TA; Media, J; Shaw, J; Tenney, K; Valeriote, FA, 2010)		0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
macrolideA macrocyclic lactone with a ring of twelve or more members derived from a polyketide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID344912Cytotoxicity against mouse Colon 38 cells at 1.1 uM by disk diffusion soft agar colony formation assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID638664Stabilization of microtubule in human HeLa cells at 20 ug/ml after 24 hrs by Hoechst staining-based fluorescence microscopic analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID638669Antiproliferative activity against human H522-T1 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID344909Disruption of microfilament in rat A10 cells at 9 uM after 18 hrs using DAPI staining by fluorescence microscopy2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID344907Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID638665Induction of microfilament disruption in human HeLa cells at 20 ug/ml after 24 hrs by Hoechst staining-based fluorescence microscopic analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID344908Ratio of IC50 for human MDA-MB-435 cells to IC50 for human HCT116 cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID638670Antiproliferative activity against human U937 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID638667Antiproliferative activity against human MDA-MB-435 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID344906Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.
AID638666Antitrypanosomal activity against Trypanosoma brucei brucei clone 427-221a assessed as growth inhibition after 40 hrs by ATP-bioluminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
AID638668Antiproliferative activity against human HT-29 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.75 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		3.1950thiazolidine
latrunculin a
latrunculin A: 16-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin B; structure given in first source. latrunculin A : A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes.		2.9940cyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone		actin polymerisation inhibitor;
metabolite;
toxin
latrunculin b
latrunculin B: 14-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin A; structure given in first source. latrunculin B : A macrolide consisting of a 14-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica.		2.4720cyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone		actin polymerisation inhibitor;
metabolite;
toxin
laulimalide
laulimalide: isolated from Cacospongia mycofijiensis; structure in first source. laulimalide : A macrolide with formula C30H42O7 that is isolated from the marine sponges, Cacospongia mycofijiensis and Hyattella sp.		2.0610carboxylic ester;
epoxide;
macrolide;
secondary alcohol;
secondary allylic alcohol		animal metabolite;
antimitotic;
antineoplastic agent;
marine metabolite;
microtubule-stabilising agent
spongia-13(16),14-dien-19-oic acid
spongia-13(16),14-dien-19-oic acid : A tetracyclic diterpenoid that is 3b,4,5,5a,6,7,8,9,9a,9b,10,11-dodecahydrophenanthro[1,2-c]furan substituted by methyl groups at positions 3b, 6 and 9 and a carboxy group at position 6. Isolated from Spongia, it exhibits inhibitory activity against androgen receptor.		2.0610cyclic ether;
monocarboxylic acid;
tetracyclic diterpenoid		androgen antagonist;
metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.1510
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.1510